Navigation Links
Novartis files application with FDA for Zometa

Novartis Pharmaceuticals has submitted an application to the Food and Drug Administration, seeking marketing authorization for Zometa in the treatment of bone complications associated with a broad range of tumor types. These include prostate and lung cancer, for which no bisphosphonate therapy is currently approved. The spread of cancerous cells from the original tumor to the bone, can lead to serious complications called skeletal related events like fractures, compression of the spinal cord, severe bone pain and hypercalcemia.//

Zometa is a new generation intravenous bisphosphonate that was approved by the FDA just two weeks ago (20 August 2001) for the treatment of hypercalcemia of malignancy (HCM), the most common life-threatening metabolic complication of cancer. To date, Novartis has received marketing clearances for Zometa in the treatment of hypercalcemia of malignancy (HCM) in more than 30 countries.

"Bone complications can be extremely debilitating to cancer patients, and seriously impact their day to day activities. Zometa offers these patients an effective treatment with a convenient 15-minute infusion time. Novartis is pleased to bring forward another drug that will help make a marked difference in the lives of cancer patients and their families" said David Epstein, President, Novartis Oncology.

Three trials have been successfully conducted, evaluating more than 3,000 patients. This is the largest set of clinical trials ever conducted to evaluate the efficacy and tolerability of bisphosphonates in treating bone complications.


'"/>




Page: 1

Related medicine news :

1. Canine Painkiller unveiled by Novartis
2. Glivec the hot cancer drug from Novartis
3. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
4. Novartis MS Drug Shows Promising Results
5. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
6. Drop Patent Petition, Activists Ask Novartis
7. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
8. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
9. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
10. Novartis Drug Diovan Shows Superior Benefits
11. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
Breaking Medicine Technology: